Search

Grifols SA

Suletud

SektorRahandus

11.285 -0.83

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

11.27

Max

11.305

Põhinäitajad

By Trading Economics

Sissetulek

57M

117M

Müük

-85M

1.9B

P/E

Sektori keskmine

25.977

27.91

Aktsiakasum

0.19

Dividenditootlus

1.28

Kasumimarginaal

6.19

Töötajad

23,833

EBITDA

-135M

347M

Soovitused

By TipRanks

Soovitused

Neutraalne

12 kuu keskmine prognoos

+6.1% upside

Dividendid

By Dow Jones

Dividenditootlus

Sektori keskmine

1.28%

4.01%

Järgmine tulemuste avaldamine

4. nov 2025

Turustatistika

By TradingEconomics

Turukapital

3.1B

6.9B

Eelmine avamishind

12.12

Eelmine sulgemishind

11.285

Uudiste sentiment

By Acuity

50%

50%

206 / 528 Pingereas Finance

Tehniline skoor

By Trading Central

Kindlus

Bearish Evidence

Grifols SA Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

2. apr 2025, 17:19 UTC

Omandamised, ülevõtmised, äriostud

Grifols in 'Very Preliminary Talks' With Brookfield Over Renewed Takeover Bid -- 2nd Update

2. apr 2025, 13:02 UTC

Omandamised, ülevõtmised, äriostud

Grifols, Brookfield Deny Takeover Talks After Report of Renewed Interest -- Update

2. apr 2025, 10:13 UTC

Omandamised, ülevõtmised, äriostud

Grifols Board Denies Media Reports Over Talks With Brookfield for Another Takeover Bid

28. juuli 2025, 10:51 UTC

Market Talk

U.S.-EU Tariff Deal, Earnings Could Keep Pharma Rally Going -- Market Talk

15. apr 2025, 09:55 UTC

Market Talk

U.S Pharma Import Probe Clouds Clarity for EU Companies -- Market Talk

2. apr 2025, 09:27 UTC

Kuumad aktsiad

Stocks to Watch Wednesday: Tesla, Newsmax, Novo Nordisk -- WSJ

Grifols SA Prognoos

Hinnasiht

By TipRanks

6.1% tõus

12 kuu keskmine prognoos

Keskmine 12 EUR  6.1%

Kõrge 12 EUR

Madal 12 EUR

Põhineb 1 Wall Streeti analüütiku instrumendi Grifols SA 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Neutraalne

1 ratings

0

Osta

1

Hoia

0

Müü

Tehniline skoor

By Trading Central

N/A / 8.566Toetus ja vastupanu

Lühikene perspektiiv

Bearish Evidence

Keskpikk perspektiiv

Very Strong Bearish Evidence

Pikk perspektiiv

Bearish Evidence

Sentiment

By Acuity

206 / 528 Pingereas Rahandus

Uudiste sentiment

Neutral

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Alla keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Grifols SA

Grifols, S.A. operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand's disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer's disease. It markets diagnostic testing equipment, reagents, and other equipment; biological products; manufactures and sells plasma to third parties; and involves in research activities, as well as markets pharmaceutical products for hospital pharmacies. In addition, the company offers Yimmugo PID, an immunology drug; and Yimmugo ITP, a hematology drug. Further, it develops Xembify Pre-filled syringes, FlexBag, and Prolastin vials; Xembify Biweekly dosing, Prolastin-C, Fostamatinib2, and VISTASEAL which are in Phase IV development stage; Xembify, Albumin 20% and 5%, Fibrinogen, Trimodulin, Cytotec pregnancy, and AMBAR-Next in Phase III development stage; and AKST4290 that is in Phase II clinical development. Additionally, it offers recIG, Alpha-1 AT in non-cystic fibrosis bronchiectasis, ATIII, GIGA 2339, GIGA564, and OSIG. It has collaboration agreements with Canadian Blood Services for the processing of other plasma-derived products and with GIANT; and GigaGen to develop recombinant polyclonal immunoglobulin therapies. The company was founded in 1909 and is headquartered in Barcelona, Spain.
help-icon Live chat